HONG KONG, Feb 18, 2022 - (ACN Newswire) - EC Healthcare (the Company, which together with its vehicles is referred to as the Group, HKG: 2138), the largest non-hospital medical group in Hong Kong *, is pleased to announce that the Group has been selected and will be included as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from 7 March 2022:

(1) Hang Seng Composite SmallCap Index
(2) Hang Seng Small Cap (Investable) Index
(3) Hang Seng Healthcare Index
(4) Hang Seng Stock Connect Hong Kong Index
(5) Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
( 6) Hang Seng Stock Connect Hong Kong SmallCap Index
(7) Hang Seng SCHK HK Companies Index
(8) Hang Seng SCHK ex-AH Companies Index

The Hang Seng Composite Index (HSCI) serves as a comprehensive Hong Kong market. HSCI covers the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong (SEHK). Adopting The free-float-adjusted market capitalization methodology, HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. The HSCI inclusion also implies that the Company is eligible for stocks for Stock Connect, which is an important scheme for mutual stock. As EC Healthcare becomes eligible stocks for Stock Connect, the mainland investors can directly trade the Company's stock. Are able to deal in the Company's shares directly. This demonstrates the market's recognition of the Company's long-term value and growth potential.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The inclusion of EC Healthcare in the Hang Seng Composite Index demonstrates the capital market's recognition of the Group's growth potential. Eligible for the Hong Kong Stock Connect, EC Healthcare will be able to further expand its shareholder base and trading liquidity, resulting in the realization of the value of an investment in the Company and enhancement of the Company's reputation in the capital market. Looking ahead, the Group This will enable us to provide health management services to more people, create greater value for our clients, will continue to refine its business capabilities and further build up the enclosed ecosystem through organic growth as well as mergers and acquisition. 

Thereby creating greater returns for shareholders and leading the industry in upgrading and development. "

About EC Healthcare

EC Healthcare is Hong Kong's largest non-hospital medical service provider *, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by The Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the MSCI Small Cap Index and the Hang Seng Composite Index.

The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN. which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services center SPINE Central, New York Spine and Physiotherapy Center NYMG, health management center re: HEALTH, a vaccine center Hong Kong Professional Vaccine HKPV , a comprehensive dental center UMH DENTAL CARE, a diagnostic and imaging center HKAI, an oncology treatment center reVIVE, a day procedure center HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER,obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional haircare center HAIR FOREST, Ophthalmology Center VIVID EYE Imaging Center.

* According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Charmaine Ip
Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 
Fax: (852) 3170 6606
Email: ech@iprogilvy.com